In vitro and in vivo mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar sodium

Journal of Immunology

Volumn 160, Issue 2, 1998, Pages 846-853

  Xu, Xiulong ^a   Williams, James W ^a   Shen, Jikun ^a   Gong, Haihua ^a   Yin, Deng Ping ^a   Blinder, Leonard ^a   Elder, Robert T ^a   Sankary, Howard ^a   Finnegan, Alison ^a   Chong, Anita S F ^a,b  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREQUINAR; DIHYDROOROTATE DEHYDROGENASE; IMMUNOSUPPRESSIVE AGENT; TYROSINE; URIDINE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INACTIVATION; GRAFT REJECTION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PYRIMIDINE SYNTHESIS; T LYMPHOCYTE;

ANIMALS; BIPHENYL COMPOUNDS; BONE MARROW; CELLS, CULTURED; DRUG THERAPY, COMBINATION; GROWTH INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; PHOSPHORYLATION; SPLEEN; TYROSINE; URIDINE;

EID: 0031964255     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Noe, D., E. Rowinsky, H. Shen, B. Clarke, L. Grochow, W. McGuire, A. Hantel, D. Adams, M. Abeloff, D. Ettinger, and R. Donehower. 1990. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390). Cancer Res. 49:4648.
2. Cody, R., M. Stewart, M. de Forni, and M. Lopez. 1991. A phase II study of brequinar sodium (DUP 785, NSC 368390) in breast cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 10:A118.
3. Dexter, D., D. Hesson, R. Ardecky, G. Rao, D. Tippett, B. Dusak, K. Paull, J. Plowman, D. DeLarco, V. Narayan, and M. Forbes. 1985. Activity of a novel 4-quinoline carboxylic acid. NSC 368390 [6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt], against experimental tumors. Cancer Res. 45:5563.
4. Jaffee, B., E. Jones, S. Loveless, and S. Chen. 1993. The unique immunosuppressive activity of brequinar sodium. Transplant Proc. 25:19.
5. Cramer, D., F. Chapman, and B. Jaffee. 1992. The prolongation of concordant hamster-to-rat cardiac xenografts by brequinar sodium. Transplantation 54:403.
6. Cramer, D., F. Chapman, B. Jaffee, E. Jones, M. Knoop, G. Hreha-Eiras, and L. Makowka. 1992. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation 53:303.
7. Makowka, L., F. Chapman, and D. Cramer. 1993. Historical development of brequinar sodium as a new immunosuppressive drug for transplantation. Transplant Proc. 25:2.
8. Makowka, L., L. Sher, and D. Cramer. 1993. The development of brequinar as an immunosuppressive drug for transplantation. Immunol. Rev. 136:51.
9. Chen, S., L. Papp, R. Ardecky, G. Rao, D. Hesson, M. Forbes, and D. Dester. 1990. Structure-activity relationship of quinoline carboxylic acids: a new class of inhibitors of dihydroortate dehydrogenase. Biochem. Pharmacol. 40:709.
10. Chen, S.-F., R. L. Ruben, and D. L. Dexter. 1986. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res. 46:5014.
11. Peters, G., S. Sharma, E. Leurensse, and H. Pinedo. 1987. Inhibition of pyrimidine de novo synthesis by DUP785 (NSC 368390). Invest. New Drugs 5:235.
12. Tamura, K., J. Woo, M. T. Bakri, and A. W. Thomson. 1993. Brequinar sodium inhibits interleukin-6-induced differentiation into IgM-secretin plasma cells. Immunology 79:587.
13. Woo, J., B. Lemster, K. Tamura, T. E. Starzl, and A. W. Thomson. 1993. The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Transplantation 56:374.
14. Karle, J., L. Anderson, D. Dietrick, and R. Cysyk. 1980. Determination of serum and plasma uridine levels in mice, rats and humans by high-pressure liquid chromatography. Anal. Biochem. 109:41.
15. Moyer, J., J. Oliver, and R. Handschumacher. 1981. Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res. 41:3010.
16. Pizzorno, G., R. Wiegand, S. Lentz, and R. Handschumacher. 1992. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleoside pools. Cancer Res. 52:1660.
17. Webster, D., D. Becroft, and D. Suttle. 1995. Hereditary orotic aciduria and other disorders of pyrimidine metabolism. in The Metabolic and Molecular Bases of Inherited Disease. C. Scriver, A. Beaudet, W. Sly, and D. Valle., eds. McGraw-Hill. Inc., New York, p. 1799-1837.
18. Girot, R., M. Hamet, J.-L. Perignon, M. Guesnu, R. Fox, P. Cartier, A. Durandy, and C. Griscelli. 1983. Cellular immune deficiency in two siblings with hereditary orotic aciduria. N. Engl. J. Med. 308:700.
19. Girot, R., A. Durandy, J.-L. Perignon, and C. Griscelli. 1983. A defect of pyrimidine metabolism with cellular immunodeficiency. Birth Defects 19:313.
20. Corry, R., H. Winn, and P. Russell. 1973. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 16:343.
21. Lyons, A., and C. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171:131.
22. Olempska-Beer, Z., and E. B. Freese. 1984. Optimal extraction for high-performance liquid Chromatographic determination of nucleotides in yeast. Anal. Biochem. 140:236.
23. Xu, X., J. W. Williams, E. G. Bremer, A. Finnegan, and A. S.-F. Chong. 1995. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 270:12398.
24. Xu, X., J. W. Williams, H. Gong, A. Finnegan, and A. S.-F. Chong. 1996. Two activities of a novel immunosuppressive agent, A77 1726 [N-(4-trifluoromethylphenyl-2-cyano-3-hydroxycrotoamide)]: inhibition of protein tyrosine phosphorylation and interference with pyrimidine synthesis. Biochem. Pharmacol. 52:527.
25. Chong, A., K. Rezai, H. Gebel, A. Finnegan, P. Foster, X. Xu, and J. Williams. 1995. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 61:140.
26. Bartlett, R. R., M. Dimitrijevic, T. Mattar, T. Zielinski, T. Germann, E. Rüde, G. H. Thoenes, C. C. A. Küchle, H.-U. Schorlemmer, E. Bremer, A. Finnegan, and R. Schleyerbach. 1991. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 32:10.
27. Seimasko, K., A. Chong, J. Williams, E. Bremer, and A Finnegan. 1995. Regulation of B cell function by the immunosuppressive agent, leflunomide. Transplantation 61:635.
28. Williams, J. W., F. Xiao, P. Foster, C. Clardy, L. McChesney, H. Sankary, and A. Chong. 1994. Leflunomide in experimental transplantation: control of rejection and alloantibody production, reversal of acute rejection and interaction with cyclosporine. Transplantation 57:1223.
29. Xiao, F., A. Chong, P. F. Foster, H. N. Sankary, L. McChesney, G. Koukoulis, J Yang, D. Freiders, and J. Williams. 1994. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 58:828.
30. Williamson, R., C. Yea, P. Robson, A. Curnock, S. Gadher, A. Hambleton, K. Woodward, J.-M. Bruneau, P. Hambleton, D. Moss, A. Thomson, S. Spinella-Jagle, et al. 1995. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 270:22467.
31. Greene, S., K. Watanabe, J. Braatz-Trulson, and L. Lou. 1995. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem. Pharmacol 50:861.
32. Davis, J., G. Cain, W. Pitts, R. Magolda, and R. Copeland. 1996. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35:1270.
33. Cherwinski, H., D. McCarley, R. Schatzman, B. Devens, and J. Ransom. 1995. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J. Pharmacol. Exp. Ther. 272:460.
34. Elder, R., X. Xu, J. Williams, H. Gong, A. Finnegan, and A. S.-F. Chong. 1997. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. 159:22.
35. Fairbanks, L., M. Bofill, K. Ruckemann, and H. Simmonds. 1995. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. J. Biol. Chem. 270:29682.
36. Seifert, M. 1989. Spleen in blood cell regulation and hematopoiesis. Hematology 10:21.
37. O'Keane, J., B. Wolf, and R. Neiman. 1989. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 63:1539.
38. Redondo, P., A. Alvarez, C. Diez, F. Fernandez-Rojo, and J. Prieto. 1995. Physiological response to experimentally induced anemia in rats: a comparative study. Lab. Anim. Sci. 45:578.
39. Tare, N., S. Bowen, R. Warrier, D. Carvajal, W. Benjamin, J. Riley, T. Anderson, and M. Gately. 1995. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J. Interferon Cytokine Res. 15:377.
40. Karle, J., L. Anderson, and R. Cysyk. 1984. Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells. J. Biol. Chem. 259: 67.
41. Shen, H., S.-F. Chen, D. Behrens, C. Whitney, D. Dexter, and M. Forbes. 1988. Distribution of the novel anticancer drug candidate brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts. Cancer Chemother. Pharmacol. 21:183.
42. Eiras-Hreha, G., D. Cramer, C. Cosenza, F. Chapman, L. Mills, E. Cajulis, D. Hill, E. Jones, I. Zajac, B. Jaffee, and L. Makowka. 1993. Brequinar sodium: monitoring immunosuppressive activity. Transplant. Proc. 1993:32.